Last reviewed · How we verify
FACT Complex-targeting Curaxin CBL0137
At a glance
| Generic name | FACT Complex-targeting Curaxin CBL0137 |
|---|---|
| Also known as | CBL0137 |
| Sponsor | Children's Oncology Group |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma (PHASE1, PHASE2)
- Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma (EARLY_PHASE1)
- CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma (PHASE1)
- A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm (PHASE1)
- Study of IV CBL0137 in Previously Treated Hematological Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: